Literature DB >> 26408334

A three-signal model of T-cell lymphoma pathogenesis.

Ryan A Wilcox1.   

Abstract

T-cell lymphoma pathogenesis and classification have, until recently, remained enigmatic. Recently performed whole-exome sequencing and gene-expression profiling studies have significant implications for their classification and treatment. Recurrent genetic modifications in antigen ("signal 1"), costimulatory ("signal 2"), or cytokine receptors ("signal 3"), and the tyrosine kinases and other signaling proteins they activate, have emerged as important therapeutic targets in these lymphomas. Many of these genetic modifications do not function in a cell-autonomous manner, but require the provision of ligand(s) by constituents of the tumor microenvironment, further supporting the long-appreciated view that these lymphomas are dependent upon and driven by their microenvironment. Therefore, the seemingly disparate fields of genomics and immunology are converging. A unifying "3 signal model" for T-cell lymphoma pathogenesis that integrates these findings will be presented, and its therapeutic implications briefly reviewed.
© 2015 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26408334      PMCID: PMC4715594          DOI: 10.1002/ajh.24203

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  98 in total

1.  ICOS receptor instructs T follicular helper cell versus effector cell differentiation via induction of the transcriptional repressor Bcl6.

Authors:  Youn Soo Choi; Robin Kageyama; Danelle Eto; Tania C Escobar; Robert J Johnston; Laurel Monticelli; Christopher Lao; Shane Crotty
Journal:  Immunity       Date:  2011-06-24       Impact factor: 31.745

2.  Autocrine IL-21 stimulation is involved in the maintenance of constitutive STAT3 activation in Sézary syndrome.

Authors:  Leslie van der Fits; Jacoba J Out-Luiting; Marieke A van Leeuwen; Janneke N Samsom; Rein Willemze; Cornelis P Tensen; Maarten H Vermeer
Journal:  J Invest Dermatol       Date:  2011-09-22       Impact factor: 8.551

3.  Autocrine/paracrine cytokine stimulation of leukemic cell proliferation in smoldering and chronic adult T-cell leukemia.

Authors:  Jing Chen; Mike Petrus; Bonita R Bryant; Vinh Phuc Nguyen; Carolyn K Goldman; Richard Bamford; John C Morris; John E Janik; Thomas A Waldmann
Journal:  Blood       Date:  2010-09-21       Impact factor: 22.113

Review 4.  An enigmatic tail of CD28 signaling.

Authors:  Jonathan S Boomer; Jonathan M Green
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-06-09       Impact factor: 10.005

5.  Discovery of recurrent t(6;7)(p25.3;q32.3) translocations in ALK-negative anaplastic large cell lymphomas by massively parallel genomic sequencing.

Authors:  Andrew L Feldman; Ahmet Dogan; David I Smith; Mark E Law; Stephen M Ansell; Sarah H Johnson; Julie C Porcher; Nazan Ozsan; Eric D Wieben; Bruce W Eckloff; George Vasmatzis
Journal:  Blood       Date:  2010-10-28       Impact factor: 22.113

6.  Recurrent loss, but lack of mutations, of the SMARCB1 tumor suppressor gene in T-cell prolymphocytic leukemia with TCL1A-TCRAD juxtaposition.

Authors:  Stefanie Bug; Jan Dürig; Florian Oyen; Ludger Klein-Hitpass; Jose I Martin-Subero; Lana Harder; Michael Baudis; Norbert Arnold; Uwe Kordes; Ulrich Dührsen; Reinhard Schneppenheim; Reiner Siebert
Journal:  Cancer Genet Cytogenet       Date:  2009-07

Review 7.  Cutaneous T-cell lymphoma: 2011 update on diagnosis, risk-stratification, and management.

Authors:  Ryan A Wilcox
Journal:  Am J Hematol       Date:  2011-11       Impact factor: 10.047

8.  T-cell receptor-driven lymphomagenesis in mice derived from a reprogrammed T cell.

Authors:  Thomas Serwold; Konrad Hochedlinger; John Swindle; Joe Hedgpeth; Rudolf Jaenisch; Irving L Weissman
Journal:  Proc Natl Acad Sci U S A       Date:  2010-10-18       Impact factor: 11.205

9.  FOXP3+CD25- tumor cells with regulatory function in Sézary syndrome.

Authors:  Julia B Heid; Angelika Schmidt; Nina Oberle; Sergij Goerdt; Peter H Krammer; Elisabeth Suri-Payer; Claus-Detlev Klemke
Journal:  J Invest Dermatol       Date:  2009-07-23       Impact factor: 8.551

10.  T-cell lymphomas in T-cell-specific Pten-deficient mice originate in the thymus.

Authors:  T J Hagenbeek; H Spits
Journal:  Leukemia       Date:  2007-11-29       Impact factor: 11.528

View more
  27 in total

Review 1.  Ontogeny, Genetics, Molecular Biology, and Classification of B- and T-Cell Non-Hodgkin Lymphoma.

Authors:  Russell James Hubbard Ryan; Ryan Alan Wilcox
Journal:  Hematol Oncol Clin North Am       Date:  2019-05-18       Impact factor: 3.722

2.  Genetic alterations affecting GTPases and T-cell receptor signaling in peripheral T-cell lymphomas.

Authors:  Rebecca L Boddicker; Gina L Razidlo; Andrew L Feldman
Journal:  Small GTPases       Date:  2017-01-06

3.  A single center phase II study of ixazomib in patients with relapsed or refractory cutaneous or peripheral T-cell lymphomas.

Authors:  Philip S Boonstra; Avery Polk; Noah Brown; Alexandra C Hristov; Nathanael G Bailey; Mark S Kaminski; Tycel Phillips; Sumana Devata; Tera Mayer; Ryan A Wilcox
Journal:  Am J Hematol       Date:  2017-09-25       Impact factor: 10.047

4.  Colony-Stimulating Factor 1 Receptor (CSF1R) Activates AKT/mTOR Signaling and Promotes T-Cell Lymphoma Viability.

Authors:  Carlos Murga-Zamalloa; Delphine C M Rolland; Avery Polk; Ashley Wolfe; Hiran Dewar; Pinki Chowdhury; Ozlem Onder; Rajan Dewar; Noah A Brown; Nathanael G Bailey; Kedar Inamdar; Megan S Lim; Kojo S J Elenitoba-Johnson; Ryan A Wilcox
Journal:  Clin Cancer Res       Date:  2019-10-21       Impact factor: 12.531

Review 5.  Soluble immune checkpoint molecules: Serum markers for cancer diagnosis and prognosis.

Authors:  Rituparna Chakrabarti; Bhavya Kapse; Gayatri Mukherjee
Journal:  Cancer Rep (Hoboken)       Date:  2019-02-07

Review 6.  Peripheral T cell lymphomas: from the bench to the clinic.

Authors:  Danilo Fiore; Luca Vincenzo Cappelli; Alessandro Broccoli; Pier Luigi Zinzani; Wing C Chan; Giorgio Inghirami
Journal:  Nat Rev Cancer       Date:  2020-04-06       Impact factor: 60.716

7.  Integrated mate-pair and RNA sequencing identifies novel, targetable gene fusions in peripheral T-cell lymphoma.

Authors:  Rebecca L Boddicker; Gina L Razidlo; Surendra Dasari; Yu Zeng; Guangzhen Hu; Ryan A Knudson; Patricia T Greipp; Jaime I Davila; Sarah H Johnson; Julie C Porcher; James B Smadbeck; Bruce W Eckloff; Daniel D Billadeau; Paul J Kurtin; Mark A McNiven; Brian K Link; Stephen M Ansell; James R Cerhan; Yan W Asmann; George Vasmatzis; Andrew L Feldman
Journal:  Blood       Date:  2016-06-13       Impact factor: 22.113

8.  International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma.

Authors:  Matthew J Maurer; Fredrik Ellin; Line Srour; Mats Jerkeman; N Nora Bennani; Joseph M Connors; Graham W Slack; Karin E Smedby; Stephen M Ansell; Brian K Link; James R Cerhan; Thomas Relander; Kerry J Savage; Andrew L Feldman
Journal:  J Clin Oncol       Date:  2017-10-26       Impact factor: 44.544

Review 9.  Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.

Authors:  Ryan A Wilcox
Journal:  Am J Hematol       Date:  2015-11-26       Impact factor: 10.047

10.  Survival following salvage therapy for primary refractory peripheral T-cell lymphomas (PTCL).

Authors:  Janie Y Zhang; Robert Briski; Sumana Devata; Mark S Kaminski; Tycel J Phillips; Tera L Mayer; Nathanael G Bailey; Ryan A Wilcox
Journal:  Am J Hematol       Date:  2017-12-18       Impact factor: 10.047

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.